Allergan Demonstrates Ongoing Commitment to Irritable Bowel Syndrome (IBS) with Development of IBS CounSEL

DUBLIN, Oct. 16, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today the formation of the IBS CounSEL, a group of multidisciplinary experts dedicated to improving diagnosis and management of irritable bowel syndrome (IBS) by providing Support, Education and Leadership (SEL) to physicians and allied healthcare professionals. The IBS CounSEL will launch their new website at the American College of Gastroenterology (ACG) Annual Scientific Meeting from October 14-19, 2016 in Las Vegas.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

IBS is a chronic gastrointestinal disorder associated with disturbances of intestinal motility, sensation, and secretion, resulting in recurrent abdominal pain and changes in bowel habits.^i,ii 
This chronic disorder affects an estimated 35 million Americans and is associated with impaired quality of life, significant disability and emotional distress, and high healthcare costs.^iii,iv,v,vi

The American Gastroenterological Association's recent "IBS in America" survey found that when physicians were asked what is lacking most in the treatment of IBS, the second-most-common answer was communication between doctors and patients. With this in mind, Allergan looked to bring together healthcare professionals to develop practical tools and provide expert guidance for physicians and allied healthcare professionals in the diagnosis and management of IBS.

"The IBS CounSEL was created to fill the necessary need for continued informed dialogue between IBS patients and their physicians," said Dr. Susan Lucak, Chair of The IBS CounSEL. "It's important in any medical discipline that we continue to hone our craft based on the latest information available. The IBS CounSEL is a group of healthcare professionals who are looking to do just that."

As part of their commitment to improving IBS education, the organization developed an interactive website. In addition to providing disease-state information, simple downloadable resources are available through diagnosis and management toolkits. 

The IBS CounSEL will have a booth on-site from October 16 -18 during the ACG Annual Scientific Meeting where the website will be demonstrated.

For additional information on IBS and to learn more about the IBS CounSEL, please visit www.ibscounsel.com.  

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

ⁱ Longstreth GF et al. Gastroenterology 2006; 130: 1480-1491.
ⁱⁱ Ford AC et al. Am J Gastroenterol 2014; 109 (Suppl 1): S2-26.
ⁱⁱⁱ Canavan C et al. Clin Epidemiol 2014; 6: 71-80
^iv Saito YA et al. Am J Gastroenterol 2002; 97: 1910-1915.
^v Drossman DA et al. Gastroenterology 2002; 123: 2108-2131.
^vi Hulisz D. J Manag Care Pharm 2004; 10: 299-309.

CONTACT:          Media:
                           Fran DeSena 
                           (973) 517-3132

SOURCE Allergan plc

Related Links

http://www.allergan.com